AUPH
Income statement / Annual
Last year (2024), Aurinia Pharmaceuticals Inc.'s total revenue was $235.13 M,
an increase of 33.97% from the previous year.
In 2024, Aurinia Pharmaceuticals Inc.'s net income was $5.75 M.
See Aurinia Pharmaceuticals Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$235.13 M |
$175.51 M |
$134.03 M |
$45.61 M |
$50.12 M |
$318.00 K |
$463.00 K |
$420.00 K |
$173.00 K |
$235.00 K |
| Cost of Revenue |
$28.25 M
|
$14.15 M
|
$5.66 M
|
$1.09 M
|
$0.00
|
$0.00
|
$41.38 M
|
$1.00 K
|
$4.00 K
|
$12.00 K
|
| Gross Profit |
$206.89 M
|
$161.37 M
|
$128.37 M
|
$44.51 M
|
$50.12 M
|
$318.00 K
|
-$40.92 M
|
$419.00 K
|
$169.00 K
|
$223.00 K
|
| Gross Profit Ratio |
0.88
|
0.92
|
0.96
|
0.98
|
1
|
1
|
-88.38
|
1
|
0.98
|
0.95
|
| Research and Development Expenses |
$20.79 M
|
$49.64 M
|
$44.99 M
|
$51.14 M
|
$50.33 M
|
$52.87 M
|
$41.38 M
|
$33.93 M
|
$14.53 M
|
$15.98 M
|
| General & Administrative Expenses |
$157.93 M
|
$195.04 M
|
$196.37 M
|
$171.44 M
|
$97.27 M
|
$22.34 M
|
$13.67 M
|
$12.10 M
|
$6.97 M
|
$6.26 M
|
| Selling & Marketing Expenses |
$14.09 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$172.03 M
|
$195.04 M
|
$196.37 M
|
$171.44 M
|
$97.27 M
|
$22.34 M
|
$13.67 M
|
$12.10 M
|
$6.97 M
|
$6.26 M
|
| Other Expenses |
$18.76 M
|
$8.38 M
|
-$1.52 M
|
$2.67 M
|
$6.81 M
|
$16.06 M
|
$2.07 M
|
$195.00 K
|
-$1.63 M
|
-$337.00 K
|
| Operating Expenses |
$211.57 M
|
$253.06 M
|
$239.84 M
|
$225.25 M
|
$154.41 M
|
$91.26 M
|
$56.62 M
|
$47.48 M
|
$22.98 M
|
$23.80 M
|
| Cost And Expenses |
$239.82 M
|
$267.20 M
|
$245.50 M
|
$226.34 M
|
$154.41 M
|
$91.26 M
|
$56.62 M
|
$47.48 M
|
$22.99 M
|
$23.82 M
|
| Interest Income |
$16.97 M
|
$17.00 M
|
$5.12 M
|
$529.00 K
|
$1.52 M
|
$2.70 M
|
$2.23 M
|
$1.04 M
|
$27.00 K
|
$50.00 K
|
| Interest Expense |
$4.84 M
|
$2.78 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$19.45 M
|
$11.65 M
|
$2.71 M
|
$2.76 M
|
$1.37 M
|
$1.17 M
|
$1.57 M
|
$1.46 M
|
$1.48 M
|
$1.56 M
|
| EBITDA |
$31.73 M |
-$63.05 M |
-$103.65 M |
-$177.45 M |
-$102.92 M |
-$89.77 M |
-$53.93 M |
-$45.61 M |
-$21.34 M |
-$22.02 M |
| EBITDA Ratio |
0.13
|
-0.36
|
-0.77
|
-3.89
|
-2.05
|
-282.3
|
-116.47
|
-108.59
|
-123.32
|
-93.71
|
| Operating Income Ratio |
-0.02
|
-0.52
|
-0.83
|
-3.96
|
-2.08
|
-285.98
|
-121.29
|
-112.05
|
-131.87
|
-100.34
|
| Total Other Income/Expenses Net |
$12.14 M
|
$14.22 M
|
$5.12 M
|
$529.00 K
|
$1.52 M
|
$2.70 M
|
$2.23 M
|
-$23.73 M
|
-$481.00 K
|
$4.97 M
|
| Income Before Tax |
$7.45 M
|
-$77.47 M
|
-$106.35 M
|
-$180.21 M
|
-$102.77 M
|
-$88.24 M
|
-$64.05 M
|
-$70.79 M
|
-$23.30 M
|
-$18.61 M
|
| Income Before Tax Ratio |
0.03
|
-0.44
|
-0.79
|
-3.95
|
-2.05
|
-277.49
|
-138.33
|
-168.55
|
-134.65
|
-79.18
|
| Income Tax Expense |
$1.70 M
|
$551.00 K
|
$1.83 M
|
$760.00 K
|
-$94.00 K
|
$144.00 K
|
$73.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
$5.75 M
|
-$78.02 M
|
-$108.18 M
|
-$180.97 M
|
-$102.68 M
|
-$88.39 M
|
-$64.12 M
|
-$70.79 M
|
-$23.30 M
|
-$18.61 M
|
| Net Income Ratio |
0.02
|
-0.44
|
-0.81
|
-3.97
|
-2.05
|
-277.94
|
-138.49
|
-168.55
|
-134.65
|
-79.18
|
| EPS |
0.04 |
-0.54 |
-0.76 |
-1.4 |
-0.87 |
-1.33 |
-0.76 |
-0.92 |
-0.66 |
-0.58 |
| EPS Diluted |
0.0393 |
-0.54 |
-0.76 |
-1.4 |
-0.87 |
-1.33 |
-0.76 |
-0.92 |
-0.66 |
-0.58 |
| Weighted Average Shares Out |
$143.06 M
|
$143.24 M
|
$141.92 M
|
$129.37 M
|
$118.47 M
|
$93.02 M
|
$84.78 M
|
$76.92 M
|
$35.29 M
|
$32.15 M
|
| Weighted Average Shares Out Diluted |
$146.19 M
|
$143.24 M
|
$141.92 M
|
$129.37 M
|
$118.47 M
|
$93.02 M
|
$84.78 M
|
$76.95 M
|
$35.29 M
|
$32.15 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
